Avion Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC W20 medical drone delivery of pharma/blood/diagnostics to remote clinics; $4.73M seed 2024-2025 with eVTOL drones and autonomous routing competing with Zipline for rural healthcare supply chain access.
About
Avion Health is a United States-based drone-based medical supply delivery platform — backed by Y Combinator (W20) with $4.73 million in seed funding in 2024-2025 — providing healthcare facilities and communities with autonomous eVTOL (electric vertical take-off and landing) drone delivery of vital medical supplies including pharmaceuticals, blood products, and diagnostic samples, bridging the accessibility gap between remote clinics and urban healthcare infrastructure. Operating pilot programs across the United States and internationally, Avion's drones feature GPS tracking, autonomous route correction, and real-time diagnostics — delivering to hard-to-reach areas with significant time savings compared to ground transportation and enabling same-hour medical supply access in geographies where traditional logistics are too slow for clinical urgency. Founded in 2019.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.